In severe or recurrent cases, caplacizumab provides rapid control of acute thrombotic thrombocytopenic purpura by inhibiting platelet-von Willebrand factor interaction, although its use in pregnancy remains limited. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.